Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00616772 · ClinicalTrials.gov registry record · Phase 3

Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood

A Phase 3 study of Coronary Artery Disease and Dyslipidemia, sponsored by AbbVie (prior sponsor, Abbott).

Completed
Registry status
Phase 3
Development phase
682
Enrollment target
20
Study locations

NCT00616772: Completed Phase 3 study of Coronary Artery Disease and Dyslipidemia, sponsored by AbbVie (prior sponsor, Abbott).

NCT00616772 is a Phase 3 study of Coronary Artery Disease and Dyslipidemia that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 682 participants, below the 1,284-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (47% lower). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00616772, a Phase 3 study of Coronary Artery Disease and Dyslipidemia, has completed, sponsored by AbbVie (prior sponsor, Abbott).

COMPLETED
Registry status
Phase 3
Development phase
682 participants
Enrollment target
20
Study locations

Study Summary

The primary purpose of this study is to test the effect and safety of once daily ABT-335 on the thickness of the lining of the carotid artery (a blood vessel to the brain) in patients with abnormal blood lipids who have optimal levels of low density lipoprotein cholesterol ("bad cholesterol") after taking atorvastatin.

Primary Outcome

Rate of change (mm/year) from baseline in mean of posterior-wall carotid intima-media thickness (cIMT) of the left and right common carotid artery. The statistical model used change from baseline as the dependent variable, with time of cIMT assessment (in years) as one of the factors in the model. The between-group difference in the rate of change was based on the parameter coefficient for the time-by-treatment interaction. The within-group rate of change was obtained from estimate statements wi

Conditions Studied

Coronary Artery Disease Dyslipidemia Coronary Heart Disease

Interventions

  • DRUG Placebo
  • DRUG ABT-335
  • OTHER Atorvastatin

Study Locations (20)

California

  • Site Reference ID/Investigator# 25082 - Anaheim
  • Site Reference ID/Investigator# 21347 - Corona
  • Site Reference ID/Investigator# 21483 - Garden Grove
  • Site Reference ID/Investigator# 21351 - Huntington Beach
  • Site Reference ID/Investigator# 21346 - Laguna Hills
  • Site Reference ID/Investigator# 21341 - Long Beach
  • Site Reference ID/Investigator# 21342 - Norwalk
  • Site Reference ID/Investigator# 21321 - Santa Ana
  • Site Reference ID/Investigator# 26242 - Tustin

Arizona

  • Site Reference ID/Investigator# 6747 - Chandler
  • Site Reference ID/Investigator# 7089 - Gilbert
  • Site Reference ID/Investigator# 7097 - Mesa
  • Site Reference ID/Investigator# 26394 - Phoenix
  • Site Reference ID/Investigator# 6848 - Scottsdale
  • Site Reference ID/Investigator# 7059 - Tempe
  • Site Reference ID/Investigator# 7094 - Tempe
  • Site Reference ID/Investigator# 7098 - Tempe

Colorado

  • Site Reference ID/Investigator# 15283 - Arvada
  • Site Reference ID/Investigator# 7085 - Aurora
  • Site Reference ID/Investigator# 6749 - Denver

Trial Details

FieldValue
Enrollment Target 682 participants
Start Date 2008-02
Est. Completion 2012-09
Phase Phase 3
AbbVie (prior sponsor, Abbott)

88 total trials

What the finished NCT00616772 record still lists

NCT00616772 is an interventional study that assigns participants to a tested intervention. The registered 682 participants enrollment target is mid-sized for trials with a published cap, below the 1,284-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (47% lower).

The record links to 3 conditions, with Coronary Artery Disease appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT00616772 names 20 study sites across 3 states, led by California, Arizona, Colorado.

Frequently Asked Questions

What is clinical trial NCT00616772 about?

NCT00616772 is a clinical study titled "Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood". The primary purpose of this study is to test the effect and safety of once daily ABT-335 on the thickness of the lining of the carotid artery (a blood vessel to the brain) in patients with abnormal blood lipids who have optimal levels of low density lipoprotein cholesterol ("bad cholesterol") after ...

What is the current status of trial NCT00616772?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 682 participants. The study started on 2008-02. Estimated completion is 2012-09.

What conditions does trial NCT00616772 study?

This clinical trial studies the following conditions: Coronary Artery Disease, Dyslipidemia, Coronary Heart Disease.

What interventions are being tested in trial NCT00616772?

The interventions under investigation include: Placebo (DRUG), ABT-335 (DRUG), Atorvastatin (OTHER).

Who is sponsoring clinical trial NCT00616772?

This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00616772 being conducted?

This trial has 20 study locations across Arizona, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Coronary Artery Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00616772's enrollment target sits among peer trials

682 65th of 219 higher than 155 of 219 other Coronary Artery Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Coronary Artery Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05382559 · 681 participants · Phase 1

    A Study of ASP3082 in Adults With Advanced Solid Tumors

  • NCT06795087 · 684 participants

    Discharge Medication Use Post-Operatively in GU Cancer Patients

  • NCT03501706 · 680 participants · NA

    An Assessment of Cognitive Improvement Training Among Mid-life Individuals

  • NCT05626452 · 680 participants · NA

    PrEP Optimization Among Women to Enhance Retention and Uptake

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00616772, the US trial registry maintained by the National Library of Medicine. NCT00616772 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.